Key Takeaways CorMedix stock is up 59.7% YTD, fueled by strong uptake of its FDA-approved drug DefenCath.DefenCath posted $78.8M in H1 2025 revenues, with full-year sales now guided to$200-$215M.CRMD's$300M Melinta buy adds seven drugs, pushing 2025 pro forma revenue outlook to $325-$350M.Shares of CorMedix (CRMD) have soared 59.7% in the year-to-date period. This stock price rally is attributable to significant investor confidence regarding the strong uptake of the company’s lead marketed drug, DefenCath ...